Dogwood Therapeutics, Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Dogwood Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2023-12-31 was $0.00.
- Dogwood Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2023-09-30 was $6.87K.
- Dogwood Therapeutics, Inc. treasury stock, value, acquired, cost method for the quarter ending 2023-06-30 was $292.25K.
- Dogwood Therapeutics, Inc. treasury stock, value, acquired, cost method for fiscal 2023 was $299.13K.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $299.13K 10-K · filed 2025-03-31 |
| 2023-09-30 | $6.87K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $292.25K 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |